{
    "eid": "2-s2.0-85061249305",
    "title": "Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report",
    "cover-date": "2019-04-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Clinical pharmacology",
        "dementia",
        "neurology",
        "pharmacotherapy",
        "statistics and study design",
        "systematic review"
    ],
    "authors": [
        "Thitiporn Supasitthumrong",
        "Blanca M. Bolea-Alamanac",
        "Selim Asmer",
        "Vincent L. Woo",
        "Petal S. Abdool",
        "Simon J.C. Davies"
    ],
    "citedby-count": 23,
    "ref-count": 91,
    "ref-list": [
        "Comparative safety and efficacy of pharmacological and non-pharmacological interventions for the behavioral and psychological symptoms of dementia: protocol for a systematic review and network meta-analysis",
        "Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study",
        "Distress associated with dementia-related psychosis and agitation in relation to healthcare utilization and costs",
        "Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians",
        "Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease",
        "Use of atypical antipsychotics in the elderly: a clinical review",
        "A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia",
        "A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia",
        "Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia",
        "Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia",
        "Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses",
        "Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials",
        "Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group",
        "Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial",
        "Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials",
        "Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm",
        "An open pilot study of citalopram for behavioral disturbances of dementia: plasma levels and real-time observations",
        "Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients",
        "A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia",
        "Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial",
        "Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study",
        "Time to response to citalopram treatment for agitation in Alzheimer disease",
        "Sertraline versus small doses of haloperidol in the treatment of agitated behavior in patients with dementia",
        "Trazodone for agitation in dementia",
        "A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease",
        "Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies",
        "Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression",
        "Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial",
        "Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients",
        "Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: a randomized double-blind pilot study",
        "Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomized, double-blind trial",
        "Relationship between the use of benzodiazepines and falls in older adults: a systematic review",
        "Review of safety and efficacy of sleep medicines in older adults",
        "Pharmacological treatment for generalized anxiety disorder in adults: an update",
        "An update on pharmacotherapy for the treatment of fibromyalgia",
        "Extended-release gabapentin in post-herpetic neuralgia",
        "Pregabalin for the treatment of fibromyalgia",
        "Pharmacotherapy of alcoholism \u2013 an update on approved and off-label medications",
        "Current pharmacological treatment approaches for alcohol dependence",
        "Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology",
        "Understanding the pharmacokinetics of anxiolytic drugs",
        "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use",
        "Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia",
        "The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia",
        "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement",
        "Use of gabapentin in the treatment of behavioural and psychological symptoms of dementia: a review of the evidence",
        "Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review",
        "Gabapentin for behavioral agitation in Alzheimer's disease",
        "Gabapentin for disruptive behaviour in an elderly demented patient",
        "Gabapentin for the management of agitation",
        "Gabapentin in the treatment of dementia-associated nocturnal agitation",
        "Gabapentin for treatment of behavioral and psychological symptoms of dementia",
        "Gabapentin in geriatric psychiatry patients",
        "Combination of donepezil and gabapentin for behavioral disorders in Alzheimer's disease",
        "Gabapentin-induced worsening of neuropsychiatric symptoms in dementia with lewy bodies: case reports",
        "Treatment of dementia-associated agitation with gabapentin",
        "Gabapentin for the treatment of behavioural alterations in dementia: preliminary 15-month investigation",
        "A retrospective chart review of gabapentin for the treatment of aggressive and agitated behavior in patients with dementias",
        "Effectiveness of gabapentin for the treatment of behavioral disorders in dementia",
        "Gabapentin and behavioral disorders in severe Alzheimer disease",
        "Use of low-dose gabapentin for aggressive behavior in vascular and mixed vascular/Alzheimer dementia",
        "[Opposition to health care in dementia: pregabalin can be useful to facilitate the management]. Opposition aux soins dans les demences: la pregabaline peut etre utile pour faciliter la prise en charge",
        "Gabapentin: a review of published experience in the treatment of bipolar disorder and other psychiatric conditions",
        "Newer antiepileptic drugs in the management of agitation/aggression in patients with dementia or developmental disability",
        "Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin",
        "[Anticonvulsant mood stabilizers in the treatment of behavioral and psychological symptoms of dementia (BPSD)]. Les antiepileptiques thymoregulateurs dans le traitement des symptomes comportementaux et psychologiques de la demence (SCPD)",
        "Anticonvulsants in the treatment of aggression in the demented elderly: an update",
        "Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review",
        "Antiepileptic drugs for the treatment of agitation and aggression in dementia: do they have a place in therapy?",
        "Gabapentin as a possible treatment of behavioral alterations in Alzheimer disease (AD) patients",
        "Frontotemporal dementia: a randomised, controlled trial with trazodone",
        "Poster 358: Gabapentin causing neurologic dysfunction leading to falls",
        "How addictive are gabapentin and pregabalin? A systematic review",
        "Predictors of gabapentin overuse with or without concomitant opioids in a commercially-insured US population",
        "Risk to heroin users of polydrug use of pregabalin or gabapentin",
        "Abuse potential of pregabalin: a systematic review",
        "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin",
        "Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data",
        "Use of pregabalin \u2013 a nationwide pharmacoepidemiological drug utilization study with focus on abuse potential",
        "Twice daily versus once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety",
        "Gabapentin misuse, abuse and diversion: a systematic review",
        "Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population",
        "The Neurontin legacy \u2013 marketing through misinformation and manipulation",
        "Evidence, regulation and \u2018rational\u2019 prescribing: the case of gabapentin for neuropathic pain",
        "Narrative review: the promotion of gabapentin: an analysis of internal industry documents",
        "Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder",
        "The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY",
        "The Concise Guide to PHARMACOLOGY 2017/18: Voltage-gated ion channels"
    ],
    "affiliation": [
        {
            "affiliation-city": "Toronto",
            "@id": "60016849",
            "affilname": "University of Toronto",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016849",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Edmonton",
            "@id": "60028825",
            "affilname": "Glenrose Rehabilitation Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028825",
            "affiliation-country": "Canada"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Toronto",
            "@id": "60015765",
            "affilname": "Centre for Addiction and Mental Health",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015765",
            "affiliation-country": "Canada"
        }
    ],
    "funding": [
        "Canadian Centre for Ageing and Brain Health Innovation",
        "Canadian Consortium for Neurodegener-ation in Aging",
        "Medical-Psychiatry Alliance",
        "Centre for Addiction and Mental Health",
        "NIHR",
        "University of Toronto"
    ]
}